文献速递中毒与环境急症消化、代谢与肾脏急症

急诊科启动丁丙诺啡治疗阿片类药物使用障碍:一项随机临床试验

Emergency Department-Initiated Buprenorphine for Opioid Use Disorder: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01
一句话结论在急诊启动7天长效注射丁丙诺啡与舌下丁丙诺啡相比,第7天治疗参与率无显著差异(40.5% vs 38.5%),两种剂型耐受良好, precipitated withdrawal 罕见。

该多中心随机临床试验纳入美国29家急诊科收治的未治疗阿片类药物使用障碍且COWS评分≥4的成人患者,比较急诊启动7天长效注射丁丙诺啡(24 mg注射,相当于16 mg/d)与舌下丁丙诺啡(COWS<8自行服用,COWS≥8急诊给予8 mg,均带7天16 mg/d处方)对第7天治疗参与率的影响。结果显示第7天调整后参与率长效组40.5% vs 舌下组38.5%(调整差1.6%,95%CI -2.8%至6.0%),第30天参与率43.8% vs 44.9%(调整差-1.5%,95%CI -6.2%至3.2%),均无显著差异。长效组第7天渴求评分更低(26.5 vs 30.2,调整均差-3.85,95%CI -7.08至-0.63),过去7天非法阿片使用天数更少(调整均数比0.77,95%CI 0.68-0.95),治疗满意度更高(调整均差0.13,95%CI 0.01-0.25)。两组precipitated withdrawal罕见(0.6% vs 0.8%),30天内过量事件均为2.3%。

要点

  • 急诊启动7天长效注射丁丙诺啡与舌下丁丙诺啡相比,第7天治疗参与率无显著差异(40.5% vs 38.5%,调整差1.6%,95%CI -2.8%至6.0%)。
  • 第30天治疗参与率同样无显著差异(43.8% vs 44.9%,调整差-1.5%,95%CI -6.2%至3.2%)。
  • 长效注射丁丙诺啡组第7天渴求评分更低(26.5 vs 30.2,调整均差-3.85,95%CI -7.08至-0.63),过去7天非法阿片使用天数更少(调整均数比0.77,95%CI 0.68-0.95)。
  • 两组precipitated withdrawal罕见(长效组0.6% vs 舌下组0.8%),30天内过量事件均为2.3%,尽管76%患者芬太尼检测阳性。
  • 长效注射丁丙诺啡组治疗满意度更高(调整均差0.13,95%CI 0.01-0.25,量表1-5分)。

适用人群与场景

  • 美国29家急诊科收治的成人患者,未治疗阿片类药物使用障碍且Clinical Opiate Withdrawal Scale(COWS)评分≥4。
  • 排除标准未在摘要中报告。

诊断标准与关键阈值

  • 未治疗阿片类药物使用障碍,COWS评分≥4。
  • 舌下丁丙诺啡组中COWS评分<8者自行服用,COWS评分≥8者在急诊给予8 mg舌下丁丙诺啡。

处置流程与药物剂量

  • 长效注射丁丙诺啡组:急诊给予24 mg长效注射丁丙诺啡(相当于16 mg/d)。
  • 舌下丁丙诺啡组:COWS评分<8者自行服用舌下丁丙诺啡;COWS评分≥8者在急诊给予8 mg舌下丁丙诺啡;所有舌下组患者获得7天16 mg/d处方。
  • 两组均提供持续药物治疗转诊,并预约7天内随访。

研究设计与关键结果

  • 多中心随机临床试验,纳入2000例随机患者,排除6例重复入组后,长效注射丁丙诺啡组991例,舌下丁丙诺啡组1003例;中位年龄37岁(IQR 30-47),68%男性,31%初始COWS评分4-7分,76%芬太尼检测阳性。
  • 主要终点:第7天阿片类药物使用障碍治疗参与率调整后为长效组40.5% vs 舌下组38.5%(调整差1.6%,95%CI -2.8%至6.0%)。
  • 关键次要终点:第30天参与率长效组43.8% vs 舌下组44.9%(调整差-1.5%,95%CI -6.2%至3.2%);precipitated withdrawal长效组6例(0.6%) vs 舌下组8例(0.8%);30天内过量事件两组均为18例(2.3%)。
  • 其他次要终点:第7天渴求评分(量表0-100)长效组26.5 vs 舌下组30.2(调整均差-3.85,95%CI -7.08至-0.63);过去7天非法阿片使用天数调整均数比0.77(95%CI 0.68-0.95);治疗满意度(量表1-5)调整均差0.13(95%CI 0.01-0.25)。

证据类型、等级与局限

  • 证据类型:多中心随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 急诊启动7天长效注射丁丙诺啡或舌下丁丙诺啡均可用于COWS评分≥4的未治疗阿片类药物使用障碍成人患者,两者第7天治疗参与率无显著差异。
  • 长效注射丁丙诺啡组第7天渴求评分更低、非法阿片使用天数更少、治疗满意度更高,但差异幅度较小。
  • 尽管76%患者芬太尼检测阳性,两组precipitated withdrawal均罕见,两种剂型耐受良好。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Extended-release injectable buprenorphine may expand the reach of initiating medications for opioid use disorder in high-risk and hard-to-reach individuals who visit the emergency department (ED) and can be administered in low levels of withdrawal.

OBJECTIVE: To compare the effect of ED-initiated 7-day extended-release injectable buprenorphine vs sublingual buprenorphine on treatment engagement at 7 days.

DESIGN, SETTING, AND PARTICIPANTS: Multicenter randomized clinical trial enrolling adult patients presenting to the ED with untreated opioid use disorder and a Clinical Opiate Withdrawal Scale (COWS) score of 4 or higher across 29 EDs in the US from July 12, 2020, to August 21, 2024. Final follow-up was completed on October 24, 2024.

INTERVENTIONS: Patients were randomized to receive a 24-mg injection of extended-release buprenorphine (equivalent to 16 mg/d) or sublingual buprenorphine, which included either self-administration instructions if the COWS score was less than 8 or administration of 8 mg of sublingual buprenorphine in the ED if the COWS score was 8 or higher. All sublingual buprenorphine group patients received a 7-day prescription for 16 mg/d. Both groups were provided referral for ongoing medication with a scheduled appointment within 7 days.

MAIN OUTCOMES AND MEASURES: Engagement in opioid use disorder treatment on day 7 was the primary outcome. Secondary outcomes included engagement at 30 days, precipitated withdrawal and overdose events, craving scores, days of illicit opioid use, and patient satisfaction with treatment.

RESULTS: Among 2000 patients randomized, 6 who were enrolled twice were excluded, resulting in 991 in the extended-release group and 1003 in the sublingual group. The median age was 37 (IQR, 30-47) years, 68% were male, 31% had an initial COWS score of 4 to 7, and 76% tested positive for fentanyl. The adjusted proportion of engagement in opioid use disorder treatment at 7 days was 40.5% with extended-release buprenorphine vs 38.5% with sublingual buprenorphine (adjusted difference, 1.6%; 95% CI, -2.8% to 6.0%). Engagement at 30 days was similar, with adjusted proportions of 43.8% with extended-release buprenorphine vs 44.9% with sublingual buprenorphine (adjusted difference, -1.5%; 95% CI, -6.2% to 3.2%). Precipitated withdrawal was rare: 6 (0.6%) with extended-release buprenorphine and 8 (0.8%) with sublingual buprenorphine. Overdose events within 30 days occurred in 18 participants (2.3%) in each group. Patients receiving extended-release buprenorphine reported lower mean craving scores at 7 days vs those receiving sublingual buprenorphine (scale, 0-100; mean score, 26.5 vs 30.2, respectively; adjusted mean difference, -3.85; 95% CI, -7.08 to -0.63), fewer days of illicit opioid use in the past 7 days (adjusted ratio of means, 0.77; 95% CI, 0.68-0.95), and better treatment satisfaction scores (scale, 1-5; adjusted mean difference, 0.13; 95% CI, 0.01-0.25).

CONCLUSIONS AND RELEVANCE: No difference was detected in opioid use disorder treatment engagement on day 7 between the 7-day extended-release and sublingual buprenorphine groups. Both buprenorphine formulations were well tolerated; precipitated withdrawal was rare despite a high prevalence of fentanyl.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04225598.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. D'Onofrio G, Herring AA, Hawk KF, et al. Emergency Department-Initiated Buprenorphine for Opioid Use Disorder: A Randomized Clinical Trial. JAMA. 2026. PMID: 41670966. doi:10.1001/jama.2025.27019

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。